S&P 500   3,313.90 (+1.00%)
DOW   27,298.09 (+0.55%)
QQQ   271.68 (+1.56%)
AAPL   111.45 (+1.24%)
MSFT   206.79 (+2.10%)
FB   253.73 (+2.25%)
GOOGL   1,454.87 (+1.73%)
AMZN   3,104.06 (+4.85%)
NVDA   502.00 (+0.26%)
TSLA   426.81 (-5.02%)
BABA   273.61 (-0.08%)
CGC   15.96 (+1.40%)
GE   6.23 (-1.89%)
MU   49.53 (+0.77%)
AMD   77.32 (-0.80%)
T   28.47 (-0.56%)
F   6.79 (-1.16%)
ACB   7.37 (+16.61%)
GILD   63.49 (-1.12%)
NFLX   489.38 (+0.42%)
DIS   126.82 (+1.12%)
BAC   23.84 (-2.57%)
BA   156.45 (+0.06%)
S&P 500   3,313.90 (+1.00%)
DOW   27,298.09 (+0.55%)
QQQ   271.68 (+1.56%)
AAPL   111.45 (+1.24%)
MSFT   206.79 (+2.10%)
FB   253.73 (+2.25%)
GOOGL   1,454.87 (+1.73%)
AMZN   3,104.06 (+4.85%)
NVDA   502.00 (+0.26%)
TSLA   426.81 (-5.02%)
BABA   273.61 (-0.08%)
CGC   15.96 (+1.40%)
GE   6.23 (-1.89%)
MU   49.53 (+0.77%)
AMD   77.32 (-0.80%)
T   28.47 (-0.56%)
F   6.79 (-1.16%)
ACB   7.37 (+16.61%)
GILD   63.49 (-1.12%)
NFLX   489.38 (+0.42%)
DIS   126.82 (+1.12%)
BAC   23.84 (-2.57%)
BA   156.45 (+0.06%)
S&P 500   3,313.90 (+1.00%)
DOW   27,298.09 (+0.55%)
QQQ   271.68 (+1.56%)
AAPL   111.45 (+1.24%)
MSFT   206.79 (+2.10%)
FB   253.73 (+2.25%)
GOOGL   1,454.87 (+1.73%)
AMZN   3,104.06 (+4.85%)
NVDA   502.00 (+0.26%)
TSLA   426.81 (-5.02%)
BABA   273.61 (-0.08%)
CGC   15.96 (+1.40%)
GE   6.23 (-1.89%)
MU   49.53 (+0.77%)
AMD   77.32 (-0.80%)
T   28.47 (-0.56%)
F   6.79 (-1.16%)
ACB   7.37 (+16.61%)
GILD   63.49 (-1.12%)
NFLX   489.38 (+0.42%)
DIS   126.82 (+1.12%)
BAC   23.84 (-2.57%)
BA   156.45 (+0.06%)
S&P 500   3,313.90 (+1.00%)
DOW   27,298.09 (+0.55%)
QQQ   271.68 (+1.56%)
AAPL   111.45 (+1.24%)
MSFT   206.79 (+2.10%)
FB   253.73 (+2.25%)
GOOGL   1,454.87 (+1.73%)
AMZN   3,104.06 (+4.85%)
NVDA   502.00 (+0.26%)
TSLA   426.81 (-5.02%)
BABA   273.61 (-0.08%)
CGC   15.96 (+1.40%)
GE   6.23 (-1.89%)
MU   49.53 (+0.77%)
AMD   77.32 (-0.80%)
T   28.47 (-0.56%)
F   6.79 (-1.16%)
ACB   7.37 (+16.61%)
GILD   63.49 (-1.12%)
NFLX   489.38 (+0.42%)
DIS   126.82 (+1.12%)
BAC   23.84 (-2.57%)
BA   156.45 (+0.06%)
Log in
NASDAQ:OSMT

Osmotica Pharmaceuticals Stock Forecast, Price & News

$5.39
-0.03 (-0.55 %)
(As of 09/22/2020 03:12 PM ET)
Add
Compare
Today's Range
$5.26
Now: $5.39
$5.43
50-Day Range
$4.82
MA: $5.56
$6.19
52-Week Range
$2.81
Now: $5.39
$9.67
Volume10,585 shs
Average Volume415,294 shs
Market Capitalization$277.70 million
P/E RatioN/A
Dividend YieldN/A
Beta3.31
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms. It also provides women's health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201 for treating Blepharoptos. In addition, the company's non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; Hydromorphone ER for treating; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate to treat hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex ANDAs and other ANDAs for various treatments. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.10 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OSMT
CUSIPN/A
CIKN/A
Phone908-809-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$240.03 million
Cash Flow$7.49 per share
Book Value$2.23 per share

Profitability

Net Income$-270,900,000.00

Miscellaneous

Employees466
Market Cap$277.70 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$5.39
-0.03 (-0.55 %)
(As of 09/22/2020 03:12 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OSMT News and Ratings via Email

Sign-up to receive the latest news and ratings for OSMT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Osmotica Pharmaceuticals (NASDAQ:OSMT) Frequently Asked Questions

How has Osmotica Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Osmotica Pharmaceuticals' stock was trading at $5.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OSMT shares have increased by 6.5% and is now trading at $5.39.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Osmotica Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Osmotica Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Osmotica Pharmaceuticals
.

When is Osmotica Pharmaceuticals' next earnings date?

Osmotica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Osmotica Pharmaceuticals
.

How were Osmotica Pharmaceuticals' earnings last quarter?

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) announced its earnings results on Tuesday, August, 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.06. The business had revenue of $37.53 million for the quarter, compared to the consensus estimate of $38.50 million. Osmotica Pharmaceuticals had a negative net margin of 73.47% and a negative return on equity of 15.61%.
View Osmotica Pharmaceuticals' earnings history
.

What price target have analysts set for OSMT?

4 equities research analysts have issued twelve-month price targets for Osmotica Pharmaceuticals' stock. Their forecasts range from $4.00 to $12.00. On average, they expect Osmotica Pharmaceuticals' stock price to reach $9.25 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price.
View analysts' price targets for Osmotica Pharmaceuticals
.

Are investors shorting Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 765,900 shares, a drop of 12.9% from the August 15th total of 879,800 shares. Based on an average daily volume of 599,100 shares, the days-to-cover ratio is presently 1.3 days. Approximately 4.9% of the company's shares are sold short.
View Osmotica Pharmaceuticals' Short Interest
.

Who are some of Osmotica Pharmaceuticals' key competitors?

What other stocks do shareholders of Osmotica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Osmotica Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Canopy Growth (CGC), Pfizer (PFE), AT&T (T), AbbVie (ABBV), Gilead Sciences (GILD), SCYNEXIS (SCYX), Zynerba Pharmaceuticals (ZYNE), AstraZeneca (AZN) and Heron Therapeutics (HRTX).

Who are Osmotica Pharmaceuticals' key executives?

Osmotica Pharmaceuticals' management team includes the following people:
  • Mr. Brian A. Markison, Chairman, Pres & CEO (Age 60)
  • Mr. Andrew J. Einhorn, Chief Financial Officer (Age 59)
  • Dr. Tina Marie deVries, Exec. VP of R&D (Age 58)
  • Mr. James D. Schaub, Exec. VP & COO (Age 37)
  • Mr. Christopher A. Klein, Gen. Counsel & Sec. (Age 55)

When did Osmotica Pharmaceuticals IPO?

(OSMT) raised $58 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 8,300,000 shares at $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities served as the underwriters for the IPO.

What is Osmotica Pharmaceuticals' stock symbol?

Osmotica Pharmaceuticals trades on the NASDAQ under the ticker symbol "OSMT."

Who are Osmotica Pharmaceuticals' major shareholders?

Osmotica Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Marshall Wace LLP (0.43%), AQR Capital Management LLC (0.25%), Wedge Capital Management L L P NC (0.23%), Globeflex Capital L P (0.19%), Charles Schwab Investment Management Inc. (0.18%) and Russell Investments Group Ltd. (0.16%).
View institutional ownership trends for Osmotica Pharmaceuticals
.

Which institutional investors are selling Osmotica Pharmaceuticals stock?

OSMT stock was sold by a variety of institutional investors in the last quarter, including Sunbelt Securities Inc., Wedge Capital Management L L P NC, Marshall Wace LLP, Jacobs Levy Equity Management Inc., and Russell Investments Group Ltd..
View insider buying and selling activity for Osmotica Pharmaceuticals
.

Which institutional investors are buying Osmotica Pharmaceuticals stock?

OSMT stock was bought by a variety of institutional investors in the last quarter, including Globeflex Capital L P, Joel Isaacson & Co. LLC, Prudential Financial Inc., Goldman Sachs Group Inc., Charles Schwab Investment Management Inc., Nuveen Asset Management LLC, Hancock Whitney Corp, and Engineers Gate Manager LP.
View insider buying and selling activity for Osmotica Pharmaceuticals
.

How do I buy shares of Osmotica Pharmaceuticals?

Shares of OSMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Osmotica Pharmaceuticals' stock price today?

One share of OSMT stock can currently be purchased for approximately $5.39.

How big of a company is Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals has a market capitalization of $277.70 million and generates $240.03 million in revenue each year. The company earns $-270,900,000.00 in net income (profit) each year or $0.25 on an earnings per share basis. Osmotica Pharmaceuticals employs 466 workers across the globe.

What is Osmotica Pharmaceuticals' official website?

The official website for Osmotica Pharmaceuticals is www.osmotica.com.

How can I contact Osmotica Pharmaceuticals?

Osmotica Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-809-1300 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.